Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy
- PMID: 38140046
- PMCID: PMC10747133
- DOI: 10.3390/pharmaceutics15122705
Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy
Abstract
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria. However, it is hindered by the lack of stability data for the administration of antibiotics under OPAT conditions. Our objective was to investigate the stability of nine antipseudomonal and broad-spectrum beta lactam antibiotics (aztreonam, cefepime, cefiderocol, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem, meropenem/vaborbactam, and piperacillin/tazobactam) to allow the spread of OPAT programs. All the antibiotics were diluted in 500 mL 0.9% sodium chloride and stored at 4, 25, 32, and 37 °C for 72 h in two different devices (infusion bags and elastomeric pumps). The solutions were considered stable if the color, clearness, and pH remained unchanged and if the percentage of intact drug was ≥90%. All the antimicrobials remained stable 72 h under refrigerated conditions and at least 30 h at 25 °C. At 32 °C, all the antibiotics except for meropenem and meropenem/vaborbactam remained stable for 24 h or more. At 37 °C, only aztreonam, piperacillin/tazobactam, cefepime, cefiderocol, and ceftolozane/tazobactam were stable for at least 24 h. The stability results were the same in the two devices tested. All the antibiotics studied are actual alternatives for the treatment of antipseudomonal or multidrug-resistant infections in OPAT programs, although the temperature of the devices is crucial to ensure antibiotic stability.
Keywords: Pseudomonas aeruginosa; beta lactams; multidrug-resistant bacteria; outpatient parenteral antimicrobial therapy; stability.
Conflict of interest statement
L.E.L.-C. has served as a scientific advisor for Angelini, a speaker for Angelini, ViiV, Gilead, and Correvio, and as a trainer for ViiV. A.d.A. has served as a scientific advisor for Angellini, Novartis, Roche, and Cook Medical, a speaker for MSD, Pfizer, Angellini, Novartis, Roche, and ViiV, and as a trainer for MSD and Cook Medical. The remaining authors have no conflict of interest to declare.
References
-
- Behzadi P., Ambrosi C., Scribano D., Zanetti S., Sarshar M., Gajdács M., Donadu M.G. Editorial: Current perspectives on Pseudomonas aeruginosa: Epidemiology, virulence and contemporary strategies to combat multidrug-resistant (MDR) pathogens. Front. Microbiol. 2022;13:975616. doi: 10.3389/fmicb.2022.975616. - DOI - PMC - PubMed
-
- Cramer N., Nawrot M.L., Wege L., Dorda M., Sommer C., Danov O., Wronski S., Braun A., Jonigk D., Fischer S., et al. Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices. Front. Cell. Infect. Microbiol. 2022;12:992214. doi: 10.3389/fcimb.2022.992214. - DOI - PMC - PubMed
-
- WHO . Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. World Health Organization; Geneva, Switzerland: 2017. WHO/EMP/IAU/2017.12.
Grants and funding
LinkOut - more resources
Full Text Sources
